{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:27Z","timestamp":1793146647510,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2025.101359","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:12:35Z","timestamp":1766247155000},"page":"101359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety"],"prefix":"10.1016","volume":"76","author":[{"given":"Mohamed","family":"Yassin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Ghasoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulwah","family":"Al-Tourah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"AlRasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101359_bb0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101359_bb0010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/JBM.S464365","article-title":"A systematic review of the epidemiology and disease burden of congenital and immune-mediated thrombotic thrombocytopenic purpura","volume":"15","author":"Du","year":"2024","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2025.101359_bb0015","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00277-024-05993-5","article-title":"Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura","volume":"103","author":"Jones","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101359_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/1744-9987.12191","article-title":"Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed?","volume":"19","author":"Nichols","year":"2015","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.blre.2025.101359_bb0030","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","article-title":"Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Lewis","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2025.101359_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/aob-21-87","article-title":"How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?","volume":"8","author":"Zheng","year":"2023","journal-title":"Ann Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0045","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0050","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura","volume":"128","author":"Page","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101359_bb0060","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101359_bb0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101359_bb0075","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-142987","article-title":"Real-world data with the use of Caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)","volume":"136","author":"Jimenez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective cohort study (the Capla 1000+ project)","volume":"82","author":"Coppo","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.blre.2025.101359_bb0095","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2025.101359_bb0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.blre.2025.101359_bb0105","series-title":"RoB 2: a revised cochrane risk-of-bias tool for randomized trials","year":"2025"},{"key":"10.1016\/j.blre.2025.101359_bb0110","author":"Ottawa Hospital Research Institute"},{"key":"10.1016\/j.blre.2025.101359_bb0115","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103722","article-title":"Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: case series","volume":"62","author":"Albanell-Fern\u00e1ndez","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.blre.2025.101359_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1226114","article-title":"Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data","volume":"10","author":"Gavriilaki","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.blre.2025.101359_bb0130","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101359_bb0135","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018847","article-title":"Delayed normalisation of ADAMTS13 activity in acute thrombotic thrombocytopenic Purpura in the caplacizumab era","author":"Prasannan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241241525","article-title":"Outcomes and costs in patients with immune thrombotic thrombocytopenic purpura receiving front-line versus delayed Caplacizumab: a US Hospital database study","volume":"30","author":"Arnaud","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.blre.2025.101359_bb0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura","volume":"21","author":"V\u00f6lker","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101359_bb0150","author":"Cablivi (caplacizumab-yhdp)"},{"key":"10.1016\/j.blre.2025.101359_bb0155","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101359_bb0160","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101359_bb0165","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101359_bb0170","series-title":"1 Recommendations | Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | guidance","year":"2020"},{"key":"10.1016\/j.blre.2025.101359_bb0175","first-page":"3","article-title":"Caplacizumab (cablivi)","author":"CADTH","year":"2023","journal-title":"Canadian J Health Technol"},{"key":"10.1016\/j.blre.2025.101359_bb0180","first-page":"277","article-title":"Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States","volume":"31","author":"Sullivan","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.blre.2025.101359_bb0185","series-title":"Overview | caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | guidance |","year":"2020"},{"key":"10.1016\/j.blre.2025.101359_bb0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.33393\/grhta.2021.2191","article-title":"Cost-effectiveness analysis of caplacizumab in the new standard of care for immune thrombotic thrombocytopenic purpura in Italy","volume":"8","author":"Minno","year":"2021","journal-title":"Glob Region Health Technol Assessm"},{"key":"10.1016\/j.blre.2025.101359_bb0195","series-title":"Caplacizumab (cablivi)","year":"2023"},{"key":"10.1016\/j.blre.2025.101359_bb0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MBC.0000000000001313","article-title":"Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"35","author":"Peng","year":"2024","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2025.101359_bb0205","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jha2.833","volume":"5","author":"Neupane","year":"2024","journal-title":"EJHaem"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:11:36Z","timestamp":1788221496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S0268960X25001043"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101359","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101359"}}